GeNeuro announced that its Chief Scientific Officer, Dr. Hervé Perron, unveiled at the “The Lancet Summit: Presymptomatic Prevention and Treatment of Neurodegenerative Diseases” additional results from the preclinical research program in Amyotrophic lateral sclerosis (ALS) developed in partnership with the National Institute of Neurological Disorders and Stroke (NINDS), part of the U.S. National Institutes of Health (NIH). These results, following those presented by Dr. Avindra Nath at the American Neurological Association (ANA) annual meeting on October 17, 2021, show in vitro and in vivo the neurotoxic effects specifically mediated by HERV-K ENV, a retroviral envelope protein encoded by a pathogenic member of the HERV-K family of endogenous human retroviruses (HERV-K ENV protein). More importantly, they confirm the neutralizing effects of GeNeuro’s novel specific monoclonal anti-HERV-K antibody. As previously mentioned, GeNeuro’s preclinical development program has enabled its anti-HERV-K ENV antibody to now be humanized and ready to enter GMP manufacturing. The program could start clinical trials as early as 2022.